Biomind Labs (NEOE:BMND) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biomind Labs's annualized Gross Profit for the quarter that ended in Sep. 2023 was C$0.00 Mil. Biomind Labs's average Total Assets over the quarter that ended in Sep. 2023 was C$0.18 Mil. Therefore, Biomind Labs's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 0.00%.

Biomind Labs Gross-Profit-to-Asset % Historical Data

The historical data trend for Biomind Labs's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Gross-Profit-to-Asset % Chart

Biomind Labs Annual Data

Trend

Dec21

Dec22

Gross-Profit-to-Asset %

Biomind Labs Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Biomind Labs's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Biomind Labs's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomind Labs's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Gross-Profit-to-Asset % falls into.

Biomind Labs Gross-Profit-to-Asset % Calculation

Biomind Labs's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0	/	( (3.236	+	0.121)	/ 2 )
	=	0	/	1.6785
	=	0.00 %

Biomind Labs's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	0	/	( (0.146	+	0.214)	/ 2 )
	=	0	/	0.18
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Biomind Labs Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomind Labs (NEOE:BMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (NEOE:BMND) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

3XI:Germany

Address

Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000

Website

https://www.biomindlabs.com

Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (NEOE:BMND) Headlines

No Headlines